Correlation of specialized CD16+ γδ T cells with disease course and severity in multiple sclerosis

Journal of Neuroimmunology

Volumn 194, Issue 1-2, 2008, Pages 147-152

  Chen, Zhihong ^a,b   Freedman, Mark S ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

T cells; Fc receptor III (CD16); IL 15; Multiple sclerosis; Progression; Proinflammatory cytokine

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 2;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTIGENS, CD; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-15; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, IGG; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 39849104447     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.11.010     Document Type: Article

References (44)

1. Abdul-Majid K.B., Stefferl A., Bourquin C., Lassmann H., Linington C., Olsson T., Kleinau S., and Harris R.A. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand. J. Immunol. 55 (2002) 70-81
2. Angelini D.F., Borsellino G., Poupot M., Diamantini A., Poupot R., Bernardi G., Poccia F., Fournie J.J., and Battistini L. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104 (2004) 1801-1807
3. Bjartmar C., Wujek J.R., and Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206 (2003) 165-171
4. Bodman-Smith M.D., Anand A., Durand V., Youinou P.Y., and Lydyard P.M. Decreased expression of FcgammaRIII (CD16) by gammadelta T cells in patients with rheumatoid arthritis. Immunology 99 (2000) 498-503
5. Butcher S.K., Chahal H., Nayak L., Sinclair A., Henriquez N.V., Sapey E., O'Mahony D., and Lord J.M. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. J. Leukoc. Biol. 70 (2001) 881-886
6. Caccamo N., Meraviglia S., Ferlazzo V., Angelini D., Borsellino G., Poccia F., Battistini L., Dieli F., and Salerno A. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur. J. Immunol. 35 (2005) 1764-1772
7. Dieli F., Poccia F., Lipp M., Sireci G., Caccamo N., Di Sano C., and Salerno A. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 198 (2003) 391-397
8. Dunne J., Lynch S., O'Farrelly C., Todryk S., Hegarty J.E., Feighery C., and Doherty D.G. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J. Immunol. 167 (2001) 3129-3138
9. Eberl M., Engel R., Beck E., and Jomaa H. Differentiation of human gamma-delta T cells towards distinct memory phenotypes. Cell. Immunol. 218 (2002) 1-6
10. Fisch P., Malkovsky M., Braakman E., Sturm E., Bolhuis R.L., Prieve A., Sosman J.A., Lam V.A., and Sondel P.M. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J. Exp. Med. 171 (1990) 1567-1579
11. Freedman M.S., Bitar R., and Antel J.P. Gamma delta T-cell-human glial cell interactions. II. Relationship between heat shock protein expression and susceptibility to cytolysis. J. Neuroimmunol. 74 (1997) 143-148
12. Freedman M.S., Ruijs T.C., Selin L.K., and Antel J.P. Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes. Ann. Neurol. 30 (1991) 794-800
13. Halary F., Peyrat M.A., Champagne E., Lopez-Botet M., Moretta A., Moretta L., Vie H., Fournie J.J., and Bonneville M. Control of self-reactive cytotoxic T lymphocytes expressing gamma delta T cell receptors by natural killer inhibitory receptors. Eur. J. Immunol. 27 (1997) 2812-2821
14. Hintzen R.Q., and Polman C.H. Th-cell modulation in multiple sclerosis. Immunol. Today 18 (1997) 507-508
15. Jefferis R., and Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol. Lett. 82 (2002) 57-65
16. Killestein J., Den Drijver B.F., Van der Graaff W.L., Uitdehaag B.M., Polman C.H., and Van Lier R.A. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult. Scler. 7 (2001) 145-150
17. Kobayashi Y., Kawai K., Ito K., Honda H., Sobue G., and Yoshikai Y. Aggravation of murine experimental allergic encephalomyelitis by administration of T-cell receptor gammadelta-specific antibody. J. Neuroimmunol. 73 (1997) 169-174
18. Lafont V., Liautard J., Liautard J.P., and Favero J. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J. Immunol. 166 (2001) 7190-7199
19. Lamour A., Smith M.D., Lydyard P.M., and Youinou P.Y. The majority of Fc gamma RIII-positive gamma delta T cells do not express HLA-DR in patients with primary Sjogren's syndrome. Immunol. Lett. 45 (1995) 153-155
20. Leclercq G., Debacker V., de Smedt M., and Plum J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 184 (1996) 325-336
21. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (1996) 907-911
22. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
23. Merrill J.E., and Benveniste E.N. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 19 (1996) 331-338
24. Myhr K.M., Raknes G., Nyland H., and Vedeler C. Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Neurology 52 (1999) 1771-1776
25. O'Riordan J.I., Thompson A.J., Kingsley D.P., MacManus D.G., Kendall B.E., Rudge P., McDonald W.I., and Miller D.H. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121 Pt 3 (1998) 495-503
26. Poggi A., Zocchi M.R., Carosio R., Ferrero E., Angelini D.F., Galgani S., Caramia M.D., Bernardi G., Borsellino G., and Battistini L. Transendothelial migratory pathways of V delta 1+TCR gamma delta+ and V delta 2+TCR gamma delta+ T lymphocytes from healthy donors and multiple sclerosis patients: involvement of phosphatidylinositol 3 kinase and calcium calmodulin-dependent kinase II. J. Immunol. 168 (2002) 6071-6077
27. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., and Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
28. Ponomarev E.D., Novikova M., Yassai M., Szczepanik M., Gorski J., and Dittel B.N. Gamma delta T cell regulation of IFN-gamma production by central nervous system-infiltrating encephalitogenic T cells: correlation with recovery from experimental autoimmune encephalomyelitis. J. Immunol. 173 (2004) 1587-1595
29. Pouly S., and Antel J.P. Multiple sclerosis and central nervous system demyelination. J. Autoimmun. 13 (1999) 297-306
30. Raine C.S. The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann. Neurol. 36 (1994.) S61-S72
31. Rajan A.J., Gao Y.L., Raine C.S., and Brosnan C.F. A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse. J. Immunol. 157 (1996) 941-949
32. Rentzos M., Cambouri C., Rombos A., Nikolaou C., Anagnostouli M., Tsoutsou A., Dimitrakopoulos A., Triantafyllou N., and Vassilopoulos D. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J. Neurol. Sci. 241 (2006) 25-29
33. Saikali P., Antel J.P., Newcombe J., Chen Z., Freedman M., Blain M., Cayrol R., Prat A., Hall J.A., and Arbour N. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J. Neurosci. 27 (2007) 1220-1228
34. Shen Y., Zhou D., Qiu L., Lai X., Simon M., Shen L., Kou Z., Wang Q., Jiang L., Estep J., Hunt R., Clagett M., Sehgal P.K., Li Y., Zeng X., Morita C.T., Brenner M.B., Letvin N.L., and Chen Z.W. Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science 295 (2002) 2255-2258
35. Solana R., and Mariani E. NK and NK/T cells in human senescence. Vaccine 18 (2000) 1613-1620
36. Stinissen P., Vandevyver C., Medaer R., Vandegaer L., Nies J., Tuyls L., Hafler D.A., Raus J., and Zhang J. Increased frequency of gamma delta T cells in cerebrospinal fluid and peripheral blood of patients with multiple sclerosis. Reactivity, cytotoxicity, and T cell receptor V gene rearrangements. J. Immunol. 154 (1995) 4883-4894
37. Szalai A.J., Hu X., Raman C., and Barnum S.R. Requirement of the Fc receptor common gamma-chain for gamma delta T cell-mediated promotion of murine experimental autoimmune encephalomyelitis. Eur. J. Immunol. 35 (2005) 3487-3492
38. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375 (1995) 155-158
39. Vaknin-Dembinsky A., and Weiner H.L. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy. J. Neurol. Sci. 259 (2007) 90-94
40. van Boxel-Dezaire A.H., Smits M., van Trigt-Hoff S.C., Killestein J., van Houwelingen J.C., Polman C.H., and Nagelkerken L. Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis. J. Neuroimmunol. 120 (2001) 152-160
41. Wegner C., Esiri M.M., Chance S.A., Palace J., and Matthews P.M. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67 (2006) 960-967
42. Wucherpfennig K.W., Newcombe J., Li H., Keddy C., Cuzner M.L., and Hafler D.A. Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4588-4592
43. Zeine R., Pon R., Ladiwala U., Antel J.P., Filion L.G., and Freedman M.S. Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. J. Neuroimmunol. 87 (1998) 49-61
44. Ziemssen T., and Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun. Rev. 4 (2005) 460-467